Back to results
US 2013/0252929 A1Published application
Pharmaceutical composition including mometasone furoate and azelastine hydrochloride for nasal administration
AssigneeHanlim Pharmaceutical Co., Ltd.
InventorsSang-Yong Lee, Geun-Hyeog Lee, Byong-Sun Choi, Jong-Hyeon Ryu, Jin-Ha Park, Mi-Jin O.
Life of this patent
Estimating the term…
Abstract
The present invention provides a pharmaceutical composition for nasal administration comprising mometasone furoate and azelastine hydrochloride, wherein the pharmaceutical composition comprises thaumatin as an agent for reducing bitterness and irritation.
Claims11
A pharmaceutical composition for nasal administration comprising mometasone furoate azelastine hydrochloride and thaumatin for reducing bitterness and irritation.
14 w/v % of azelastine hydrochloride;
- 0.25 w/v % of thaumatin;
- 2.0 w/v % of a mixture of microcrystalline cellulose and sodium carboxymethyl cellulose;
- 0.2 w/v % of citric acid;
- 0.28 w/v % of sodium citrate;
- 0.01 w/v % of polyoxyethylene sorbitan monooleate;
- 2.1 w/v % of glycerin;
- 6.6 w/v % of sorbitol;
- 0.1 w/v % of sodium edetate;
- 0.02 w/v % of benzalkonium chloride;
- and the remaining amount of water.
7 more elements
Dependencies are inferred from the claim text.